Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

OSTX OS Therapies Incorporated

2,1492

0,1992 (10,22%)

Pré-mercado

Última atualização: 10:04:13

Atrasado em 15 minutos

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

0001213900-25-000849.txt

OS Therapies (AMEX:OSTX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Click aqui para mais gráficos OS Therapies.

OS Therapies (AMEX:OSTX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025

Click aqui para mais gráficos OS Therapies.

Notícias OS Therapies Incorporated

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
Quarta, 29 de Janeiro de 2025 (2 dias atrás) • Business Wire

Form 8-K - Current report
Quarta, 29 de Janeiro de 2025 (2 dias atrás) • Edgar (US Regulatory)

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
Quarta, 29 de Janeiro de 2025 (2 dias atrás) • Business Wire

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
Sexta, 17 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 17 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Quarta, 15 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
Quarta, 15 de Janeiro de 2025 (2 semanas atrás) • Business Wire

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
Quarta, 15 de Janeiro de 2025 (2 semanas atrás) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Terça, 14 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Terça, 14 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Terça, 14 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Segunda, 13 de Janeiro de 2025 (3 semanas atrás) • Edgar (US Regulatory)

Mais Notícias de OS Therapies Incorporated

Índice Bovespa

Brava Energia ON

TIME FOR FUN ON

Fictor Alimentos ON

Agrogalaxy Participacoes ON

Sequoia Logistica e Tran... ON

Melnick Desenvolvimento ... ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições